InsiderTrades

Form 4 for AXSM Axsome Therapeutics, Inc.

Accepted 2026-06-09 17:17:33 ET · period of report 2026-06-09 · accession 0001193125-26-264038 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2026-06-09 17:17 2026-06-09 AXSM TABUTEAU HERRIOT CEO, Dir, 10% M - OptEx $4.95 +49.7K 56.9K +687% +$245.9K
DT 2026-06-09 17:17 2026-06-09 AXSM TABUTEAU HERRIOT CEO, Dir, 10% S - Sale+OE $241.01 -49.7K 7,229 -87% -$11.97M
DT 2026-06-09 17:17 2026-06-09 AXSM TABUTEAU HERRIOT CEO, Dir, 10% M - OptEx $0.00 -49.7K 99.3K -33% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-06-09 M A 49,670 $4.95 56,899 D — — (F1) Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. (F2) Such transaction was pursuant to a pre-approved 10b5-1 plan.
2 Common Common Stock 2026-06-09 S D 49,670 $241.01 7,229 D — — (F2) Such transaction was pursuant to a pre-approved 10b5-1 plan. (F3) Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. (F4) Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $236.11 and $244.13.
3 Derivative Stock Option (Right to Buy) 2026-06-09 M D 49,670 $0.00 99,330 D $241.01 · 2018-03-15 to 2027-03-15 49,670 Common Stock (F1) Necessary exercise of stock options set to expire due to attainment of the 10-year expiration date of such options. (F2) Such transaction was pursuant to a pre-approved 10b5-1 plan.